-
Mashup Score: 2
Introduction: Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRA) reduce mortality and hospitalizations in heart failure with reduced ejection fraction (HFrEF) but their use is limited in advanced chronic kidney disease (CKD). Methods: We carried out a systematic…
Source: http://www.eurekaselect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3#NephMadness 2023: Heart Failure Devices Region - 1 year(s) ago
Submit your picks! | NephMadness 2023 | #NephMadness | #CardiacDevices Selection Committee Member: Nisha Bansal @NishaKidneyDoc Nisha Bansal is an Associate Professor and the Arthur Stach Family En…
Source: AJKD BlogCategories: Latest Headlines, NephrologyTweet
-
Mashup Score: 0APAC Dinner Sponsored by Bayer at ACC | APAC - 1 year(s) ago
Join us for dinner and conversation with our APAC PA panel on best practice collaboration with APPs in optimal team-based cardiovascular practice. Topic: CV and Renal risk reduction in diabetes: reviewing finerenone in the Fidelio and Figaro trials; Presenter: Sanjay Sharma M.D.
Source: APACCategories: Cardiologists, Latest HeadlinesTweet-
Link to register here: https://t.co/lRLqrjIrtw Network with #cardiology #physicianassociates 03/05 6:30PM CST, learn about #cardiorenal protection and optimal CV #teambasedcare with #APPs #accfit #acccvt #NPs #PharmD @drsharma815 @BayerPharma @DrMarthaGulati @AAPAorg https://t.co/5duC0bI8Gh https://t.co/lXNa0dbVrI
-
-
Mashup Score: 1Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice - Nature Reviews Endocrinology - 1 year(s) ago
Cardiorenal diseases are common in patients with type 2 diabetes mellitus (T2DM), with substantial morbidity and premature mortality. This Review discusses how atherosclerotic cardiovascular disease and cardiorenal diseases can be prevented in T2DM, considering evidence from clinical trials and its implementation in clinical practice.
Source: NatureCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 6
Renal dysfunction is one of the strongest predictors of outcome in heart failure. Several studies have revealed that both reduced perfusion and increased congestion (and central venous pressure) contribute to worsening renal function in heart failure. This paper proposes a novel factor in the link b …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 18th Annual Houston Heart Failure Summit | Houston Methodist - 1 year(s) ago
COURSE DIRECTORSImad Hussain, MD, FACCProgram Director, Advanced Heart Failure & Transplant Cardiology FellowshipAssistant Professor of Cardiology, Academic InstituteAssistant Clinical Member, Research InstituteHouston MethodistWeill Cornell Medical CollegeJu H. Kim, MD, FACC, FHFSAAdvanced Heart Failure and Transplant CardiologyAssociate Program Director, Cardiovascular Disease…
Source: learn.houstonmethodist.orgCategories: Cardiologists, Latest HeadlinesTweet-
CALLING ALL HEALTHCARE PROFESSIONALS! Join for #HHFS2023 on Feb 4 @TXMedCenter! Hear from @RayanYousefzai, as he discusses the impact and management of #Cardiorenal Syndrome in #HeartFailure. Register now at https://t.co/3rWIicGtKZ! @WilliamZoghbi @NadeenFaza @txchapteracc #CME https://t.co/k3uX1h7CkF
-
-
Mashup Score: 5
In addition to the established cardiovascular benefits of SGLT2 inhibitors, the randomised data support their use for modifying risk of kidney disease progression and acute kidney injury, not only in patients with type 2 diabetes at high cardiovascular risk, but also in patients with chronic kidney disease or heart failure irrespective of diabetes status, primary kidney disease, or kidney…
Source: The LancetCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4#NephMadness 2022: Cardiorenal Region - 1 year(s) ago
Submit your picks! | NephMadness 2022 | #NephMadness | #CardioRenal Selection Committee Member: Nisha Bansal @NishaKidneyDoc Nisha Bansal is an Associate Professor and the Arthur Stach Family Endow…
Source: AJKD BlogCategories: Latest Headlines, NephrologyTweet
-
Mashup Score: 2Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease - 1 year(s) ago
Abstract. For the first time in many years, guideline-directed drug therapies have emerged that offer substantial cardiorenal benefits, improved quality of life
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants - 1 year(s) ago
Direct oral anticoagulants (DOAC) have progressively replaced vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (AF). DOACs cause fewer bleeding complications but other advantages of DOACs, particularly related to kidney outcomes, remain inconclusive. We studied the risks of CKD progression and AKI following DOAC and VKA administration for…
Categories: Latest Headlines, NephrologyTweet
Trans-Atlantic #cardiorenal collaborative work Liverpool team led by Prof @RangaswJ et al on “"Renalism" with RAASI use in pts Enrolled in Trials for #heartfailure with Reduced Ejection Fraction & Advanced #chronickidneydisease : A Systematic Review”https://t.co/VRGoFSh8Vi https://t.co/r5otBoaPzE